Comprehensive Study Guide for Gynecological and Breast Pathology

Fibroadenoma of the Breast

The fibroadenoma is the most frequent benign tumor of the female breast. It is characterized at the molecular level by driver mutations in the $MED12$ gene, which participate in the growth and development of the tumor. Clinically, these tumors are most common in younger women and are typically noted during a physical examination as mobile, non-painful masses.

Macroscopically, a fibroadenoma is well-delimited and mobile. It typically presents a grayish-white color and maintains an elastic or firm consistency. Small slit-like spaces covered by epithelial cells are often visible on the cut surface. The surrounding tissue is soft and resembles normal breast tissue. Histologically, two primary growth patterns are identified: the pericanalicular pattern and the intracanalicular pattern. In the pericanalicular pattern, the stroma surrounds the mammary ducts without significantly deforming them, leaving the lumens open. In the intracanalicular pattern, the stromal component compresses the ducts, distorting them into slit-like shapes. Higher magnification reveals benign glandular epithelium and well-defined borders, though the tumor lacks a true capsule.

The diagnostic protocol involves a four-step approach. First, a physical examination is performed to palpate for mobile, non-painful masses. Second, mammography is used to search for delimited densities or calcifications, the latter being particularly common in older patients. Third, breast ultrasound evaluates the internal structure of the mass. Fourth, a biopsy is utilized only when there is structural diagnostic doubt. Management depends on the clinical presentation. Route 1 involves clinical observation, which is recommended for the majority of small and stable fibroadenomas. Route 2 involves surgical excision, which is indicated if there is rapid growth of the mass, production of pain, generation of aesthetic deformity, or any clinical suspicion of malignancy.

Phyllodes Tumor of the Breast

The phyllodes tumor is a fibroepithelial tumor of the breast characterized by a proliferation of the stroma that forms a leaf-like (phyllodal) pattern. It is considered the counterpart of the fibroadenoma but is distinguished by a much higher growth rate of the stromal component. These tumors can be classified as benign, borderline, or malignant. Clinically, they manifest as a firm, mobile, and usually painless mammary mass that can reach a large size. Their appearance is nodular with multiple microcysts, and the cut surface sometimes resembles "fish flesh." These lesions are not always well-circumscribed and may have irregular borders.

Microscopically, the characteristic leaf-like pattern is an exaggerated version of the intracanalicular pattern. The epithelial component shows ducts that do not appear collapsed, despite the stromal pressure, and there is an increase in epithelial cellularity along with occasional hyperchromasia. The stromal component is the most critical factor for evaluating the aggressiveness of the tumor. It exhibits increased cellularity with spindle-shaped or elongated cells, high proliferative activity, and mitotic figures. Criteria for malignancy in phyllodes tumors include a marked increase in stromal cellularity (spindle cells with very little extracellular space), cellular atypia (variation in nuclear size and shape, pleomorphism), and hyperchromasia (intensely stained nuclei with dense chromatin). Additional malignant indicators include numerous figures of mitosis (including atypical ones), areas of tumor necrosis with loss of architecture, and the invasion of small blood vessels.

Diagnostic studies for phyllodes tumors include a physical exam to assess size, mobility, and skin changes. Mammography identifies well-delimited or lobulated masses and calcifications. Ultrasound is the study of choice for young women, showing a solid, heterogeneous mass with occasional cystic areas. Magnetic resonance imaging (MRI) is used for large or complex tumors to assess extension. A core needle biopsy is the most useful method for preoperative diagnosis. Finally, histopathological study of the surgical piece provides the definitive diagnosis. If malignancy is suspected, complementary studies such as chest X-rays or CT scans are performed to search for metastases, particularly in the lungs.

Vulvar Paget Disease

Vulvar Paget disease is a malignant epithelial tumor that represents less than $1\% \text{ of}$ all vulvar neoplasms. Although named for the vulva, this disease can also occur in the breast and axilla. It is most frequent in adult and menopausal women, typically between the ages of $60 \text{ and } 80 \text{ years}$. Characteristically, patients present with local pruritus, irritation, and a sensation of genital inflammation. The lesion may be unifocal or multifocal and can be invasive in approximately a quarter of cases, potentially presenting as occult or superficial adenocarcinomas.

Pathogenesis distinguishes between primary and secondary Paget disease. Primary Paget disease is the most frequent and originates in apocrine glands or cutaneous adnexa, with the neoplasia confined to the epidermis. Secondary Paget disease involves the epidermal dissemination of an invasive vulvar adenocarcinoma or tumors from the gastrointestinal or genitourinary tract. Macroscopically, it appears as an erythematous, eczematous, and desquamative plaque with ill-defined borders and a moist or eroded surface, often resembling chronic dermatitis, psoriasis, or fungal infections.

Histopathologically, the disease is defined by Paget cells: large cells with clear, vacuolated cytoplasm rich in mucin, and large, pleomorphic, hyperchromatic nuclei. These cells may be isolated or in nests along the epidermis, with the basement membrane remaining intact in non-invasive forms. Immunohistochemistry is vital for diagnosis. Vulvar Paget cells are positive for Cytokeratin 7 ($CK7$), Carcinoembryonic Antigen ($CEA$), $PAS/mucin$, and $EMA$. They are typically negative for $CK20$ (in primary forms) and $S-100/HMB-45$. $CK7$ is the choice marker for evaluating margins, while $P53$ is used for differential diagnosis. Treatment involves wide surgical excision with margin control and prolonged follow-up to evaluate for associated carcinomas. Prognosis is generally favorable for intraepithelial forms, but stromal invasion increases the risk of lymph node metastasis, and there is a high rate of local recurrence.

Ductal Carcinoma of the Breast

Ductal carcinoma is the most common type of breast cancer, originating in the cells lining the milk ducts. It is divided into Ductal Carcinoma In Situ ($DCIS$) and Invasive Ductal Carcinoma ($IDC$). Invasive Ductal Carcinoma represents approximately $70\% \text{ to } 80\% \text{ of}$ all invasive breast cancers and is most frequent in women over $50 \text{ years}$ of age. Risk factors include mutations in the $BRCA1$ and $BRCA2$ genes, early menarche, late menopause, nuliparity or first pregnancy after $30 \text{ years}$, obesity, and alcohol consumption.

Clinical manifestations include nipple discharge, skin changes like dimpling or retraction ("orange peel" appearance), and a hard, palpable mass with irregular consistency. Histologically, the tumor is of epithelial origin and shows an infiltrating growth pattern into adjacent mammary tissue. It has the capacity to invade lymphatic and blood vessels. Microscopically, it forms irregular cords, nests, or tubules with frequent mitosis. The tumor cells are pleomorphic (varying in size and shape) with large, hyperchromatic nuclei.

Immunohistochemistry evaluates several key markers: Estrogen Receptor ($ER$), Progesterone Receptor ($PR$), $HER2$ (overexpression or amplification), and $Ki-67$ (cellular proliferation index). $E\text{-cadherin}$ is generally positive in ductal carcinoma, helping to differentiate it from lobular carcinoma. Diagnosis is confirmed through a clinical exam, mammography, ultrasound, biopsy, and histopathological study. Treatment options include surgery (tumorectomy or mastectomy), radiotherapy, chemotherapy, hormone therapy (for $ER/PR$ positive tumors), and targeted therapies for $HER2$. Prevention through regular screening is emphasized as the best defense.

Lobular Carcinoma of the Breast

Lobular carcinoma is the second most common type of invasive breast cancer, accounting for $10\% \text{ to } 15\% \text{ of}$ all cases. The hallmark of its pathogenesis is the loss of expression of $E\text{-cadherin}$, a cell adhesion protein encoded by the $CDH1$ gene. Lobular Carcinoma In Situ ($LCIS$) is not considered invasive cancer itself but rather a risk marker indicating an increased likelihood of developing cancer in either breast. Invasive Lobular Carcinoma ($ILC$) occurs when the tumor has broken the basement membrane and spread into the mammary stroma.

Clinical symptoms include areas of thickening or hardening and the "orange peel" texture or nipple retraction. Imaging like MRI can reveal heterogeneous mass-like enhancements or nodular enhancements that conventional studies might miss. Histopathology shows neoplastic cells infiltrating the stroma, often in single-file patterns (indian file). Treatment is tailored to the case: surgery can be conservative (tumorectomy) or a mastectomy for multifocal disease. Hormone therapy is common, using $Tamoxifen$ for premenopausal women and Aromatase Inhibitors like $Letrozole$ or $Anastrozole$ for postmenopausal women. Chemotherapy is reserved for extensive lymph node involvement, and radiotherapy is indicated after conservative surgery or in high-risk mastectomy cases.

Cervical Intraepithelial Neoplasia (CIN)

Cervical Intraepithelial Neoplasia ($CIN$), or $NIC$ in Spanish, is a precancerous lesion of the cervix characterized by abnormal cell growth on the tissue surface. Major risk factors include Human Papillomavirus ($HPV$) infections, multiparity, sexually transmitted infections ($STIs$), and tobacco use. Symptomatology can include persistent leucorrhea, genital pruritus and burning, dyspareunia, dysuria, postcoital vaginal bleeding, and pelvic pain.

$CIN$ is stratified into three grades. $NIC\,I$ (Low Grade) involves mild dysplasia affecting the basal third of the squamous epithelium ($LSIL$) and has a high rate of spontaneous regression (>$60\% \text{ of cases}$). $NIC\,II$ (High Grade) involves moderate dysplasia affecting up to the lower two-thirds of the epithelium ($HSIL$). $NIC\,III$ (High Grade) involves severe dysplasia or carcinoma in situ, compromising the entire epithelial thickness with a high potential for progression to invasive carcinoma if untreated.

Macroscopic evaluation via colposcopy reveals high-grade lesions as dense acetowhite epithelium and atypical vessels or punctuation, while low-grade lesions appear as faint acetowhite epithelium or fine mosaic. Diagnosis is confirmed by cytology and directed biopsy of the most suspicious colposcopic areas. Treatment for $NIC\,I$ includes monitoring with cytology or colposcopy. For $NIC\,II \text{ and } III$, cryotherapy or the Loop Electrosurgical Excision Procedure ($LEEP$) is utilized. Differential diagnoses include cervicitis, condyloma acuminatum, and cervical cancer.

Uterine Leiomyosarcoma

Leiomyosarcomas are rare malignant tumors of the uterine smooth muscle, representing only $3\% \text{ to } 9\% \text{ of}$ all uterine cancers but approximately $70\% \text{ of}$ uterine sarcomas. They are most frequent in women over $50 \text{ years}$ of age and occur primarily in the uterine body. Clinically, they present as large, fleshy masses in the uterine wall or protruding into the cavity, causing abnormal uterine bleeding, pelvic or abdominal pain, and rapid uterine growth, especially in postmenopausal women.

Histologically, these tumors can contain epithelioid cells, which resemble epithelial cells. Diagnosis is generally established following a myomectomy or hysterectomy. The primary treatment is surgery via hysterectomy. Bilateral salpingo-oophorectomy may be performed in peri- or postmenopausal patients. Lymphadenectomy is only indicated if suspicious nodes are present. Early diagnosis is critical for the prognosis of this aggressive tumor.

Mammary Hyperplasia: Ductal and Lobular

Ductal hyperplasia is a benign proliferative lesion caused by an increase in the number of epithelial cells within the milk ducts of the breast. It is most frequent between the ages of $35 \text{ and } 55 \text{ years}$. Clinically, it may present as a palpable nodule, tenderness, or nipple discharge. Microscopically, one sees epithelial cell proliferation within dilated ducts, cellular overlapping, formation of bridges, and irregular spaces, though myoepithelial cells are preserved. The prognosis is excellent for usual ductal hyperplasia, but it significantly increases the future risk of breast carcinoma.

Lobular hyperplasia consists of an increased number of cells in the mammary lobules. The most significant form is Atypical Lobular Hyperplasia ($ALH$), which is a high-risk lesion for breast cancer development. Most patients are asymptomatic, with the condition discovered during routine mammography or biopsies for other findings. It predominates in women aged $40 \text{ to } 60 \text{ years}$ and represents $1\% \text{ to } 3\% \text{ of}$ breast biopsies. $ALH$ increases the risk of invasive breast cancer by $4 \text{ to } 5 \text{ times}$, affecting both breasts. Management for both types involves clinical and radiological follow-up (annual mammography or MRI) and pharmacological preventive measures for high-risk patients.

Granulosa Cell Tumor of the Ovary

The granulosa cell tumor originates in the granulosa cells of the ovarian follicle. It is infrequent and characterized by hormone production, especially estrogens. It is divided into two types: Adult Granulosa Cell Tumor ($AGCT$) and Juvenile Granulosa Cell Tumor ($JGCT$). The adult type is most common between $45 \text{ and } 55 \text{ years}$. Due to estrogen production, it causes abnormal vaginal bleeding and menstrual irregularities. Histologically, it shows small granulosa cells with "coffee bean" nuclear grooves and the formation of Call-Exner bodies (small spaces filled with eosinophilic fluid). These tumors are slow-growing but can recur even decades after treatment.

The juvenile type occurs in girls and young women under $30 \text{ years}$. In prepubertal girls, the excess estrogen causes precocious pseudopuberty (early development of breasts and pubic hair). It often manifests as large pelvic masses and acute abdominal pain. Histologically, they show microfollicular or solid patterns, and Call-Exner bodies are less frequent than in the adult type. Diagnostic tools include ultrasound/MRI, hormonal exams (estradiol), and tumor markers like Inhibin A and B, which are usually elevated. Treatment is surgical (oophorectomy), with the preservation of the uterus and healthy ovary in young women desiring fertility if the tumor is confined. Long-term follow-up is essential due to the risk of late recurrence.

Endometrial Hyperplasia

Endometrial hyperplasia is characterized by an abnormal increase in endometrial glands relative to the stroma. It is primarily caused by prolonged estrogen stimulation without adequate progesterone opposition (hyperestrogenism). Causes of hyperestrogenism include obesity, polycystic ovary syndrome ($PCOS$), chronic anovulation, menopause, estrogen-producing tumors, or prolonged estrogen therapy. Molecularly, inactivating mutations of the $PTEN$ gene are present in $20\% \text{ of}$ cases, a mutation also common in endometrial carcinomas.

The WHO classifies endometrial hyperplasia into two types: non-atypical and atypical. Non-atypical hyperplasia shows a "swiss cheese" appearance due to dilated glands, but nuclei remain relatively normal and some stroma is still present. Atypical hyperplasia involves exaggerated glandular proliferation with nuclear atypia (large, dark, irregular nuclei) and very little stroma, with glands appearing crowded or "back-to-back." This type is a direct precursor to endometrial adenocarcinoma.

Clinically, patients present with abnormal uterine bleeding, such as menorrhagia, metrorrhagia, or postmenopausal bleeding. Macroscopically, the endometrium appears thickened and irregular with small cysts. Differential diagnosis includes normal proliferative endometrium, polyps, endometritis, and adenocarcinoma. Treatment for non-atypical cases involves progestogens and strict histological follow-up. Atypical cases or those not responding to medical therapy often require total hysterectomy.